Literature DB >> 8238166

Fetal lung maturity is not accelerated in preeclamptic pregnancies.

E Schiff1, S A Friedman, B M Mercer, B M Sibai.   

Abstract

OBJECTIVE: Our purpose was to determine whether there is an increased incidence of pulmonary maturity in premature fetuses of preeclamptic women compared with fetuses of matched controls. STUDY
DESIGN: A matched cohort study design was used. One hundred twenty-seven strictly defined preeclamptic women who had undergone amniocentesis for pulmonary maturity assessment were matched for gestational age, race, and infant gender to nonhypertensive women with preterm labor who had undergone the same procedure. Patients with multiple gestation, ruptured membranes, diabetes, or prior glucocorticoid treatment were excluded. Lung maturity was assessed with the Lumadex foam stability index test, the lecithin/sphingomyelin ratio, and the TDx fetal lung maturity assay. In addition, the occurrence of respiratory distress syndrome was assessed in 69 of the 127 matched pairs who were also matched for mode of delivery and amniocentesis-to-delivery interval.
RESULTS: There was no significant difference in the incidence of an immature result between the preeclamptic and matched control groups (39.4% vs 38.6%). Likewise, women with mild (n = 63) and severe (n = 64) preeclampsia or with small-for-gestational-age (n = 26) and appropriate-for-gestational-age (n = 101) infants, when analyzed separately, showed no differences in comparison with their matched controls. When analyzed by gestational age subgroups, no specific gestational age range was associated with accelerated maturity. The incidence of respiratory distress syndrome in the 69 matched pairs was slightly, but not significantly, higher in the preeclampsia group (relative risk 1.43, 95% confidence interval 0.94 to 2.37).
CONCLUSION: This study does not support the contention that fetuses of preeclamptic women exhibit accelerated lung maturation.

Entities:  

Mesh:

Year:  1993        PMID: 8238166     DOI: 10.1016/0002-9378(93)90262-h

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Three alternative methods to resolve paradoxical associations of exposures before term.

Authors:  Nathalie Auger; Ashley I Naimi; William D Fraser; Jessica Healy-Profitós; Zhong-Cheng Luo; Anne Monique Nuyt; Jay S Kaufman
Journal:  Eur J Epidemiol       Date:  2016-06-20       Impact factor: 8.082

2.  Evidence to support that spontaneous preterm labor is adaptive in nature: neonatal RDS is more common in "indicated" than in "spontaneous" preterm birth.

Authors:  Joonho Lee; Hyo Suk Seong; Byoung Jae Kim; Jong Kwan Jun; Roberto Romero; Bo Hyun Yoon
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

3.  Does aggressive and expectant management of severe preeclampsia affect the neurologic development of the infant?

Authors:  Arif Aktuğ Ertekin; Bilge Kapudere; Meryem Kurek Eken; Gülşah İlhan; Şükriye Dırman; Mehmet Akif Sargın; Engin Deniz; Güner Karatekin; Ebru Çöğendez; Murat Api
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Hospitalized late preterm mild preeclamptic patients with mature lung testing: what are the risks of delivery?

Authors:  D F Lewis; J McCann; Y Wang; C Cormier; L Groome
Journal:  J Perinatol       Date:  2009-01-22       Impact factor: 2.521

5.  Risk factors and adverse perinatal outcomes among term and preterm infants born small-for-gestational-age: secondary analyses of the WHO Multi-Country Survey on Maternal and Newborn Health.

Authors:  Erika Ota; Togoobaatar Ganchimeg; Naho Morisaki; Joshua P Vogel; Cynthia Pileggi; Eduardo Ortiz-Panozo; João P Souza; Rintaro Mori
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  Comparisons of mortality and pre-discharge respiratory outcomes in small-for-gestational-age and appropriate-for-gestational-age premature infants.

Authors:  Puneet Sharma; Kathleen McKay; Ted S Rosenkrantz; Naveed Hussain
Journal:  BMC Pediatr       Date:  2004-06-08       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.